This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages without signing in

Angiotensin II receptor inhibitors in heart failure

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • the ELITE trial has examined the role of angiotensin II receptor inhibitors in the management of heart failure. This revealed that losartan and enalapril have similar effects on exercise capacity and haemodynamics (1). However the size of the study was not large enough to reliably assess effects on survival

  • in the CHARM study
    • in this study candesartan significantly reduces all-cause mortality, cardiovascular death, and heart failure hospitalizations in patients with chronic heart failure and left ventricular ejection fraction < or =40% when added to standard therapies including ACE inhibitors, beta-blockers, and an aldosterone antagonist

NICE recommend that (3):

  • consider an ARB licensed for heart failure as an alternative to an ACE inhibitor for patients with heart failure due to left ventricular systolic dysfunction who have intolerable side effects with ACE inhibitors

  • measure serum sodium and potassium, and assess renal function, before and after starting an ARB and after each dose increment

  • measure blood pressure after each dose increment of an ARB - follow the recommendations on measuring blood pressure, including measurement in people with symptoms of postural hypotension

  • once the target or maximum tolerated dose of an ARB is reached, monitor treatment monthly for 3 months and then at least every 6 months, and at any time the person becomes acutely unwell

Notes:

  • a meta-analysis concluded that, in patients with chronic heart failure or high risk acute myocardial infarction, angiotensin receptor blockers do not differ from angiotensin converting enzyme inhibitors for all cause mortality or hospital admission for heart failure (4)
  • ARBs in heart failure with preserved left ventricular ejecation fraction
    • study evidence revealed that irbesartan did not improve the outcomes of patients with heart failure and a preserved left ventricular ejection fraction (ejection fraction >= 45%)

Reference:

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.